Clinical Trial Update: Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies [Phase 2]

View source ↗

Summary

A Phase 2 study on precision phenotyping of behavioral risk and response to electromagnetic and psychedelic therapies for suicidal ideation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Suicidal Ideation

Snippet

Sponsor: University of New Mexico | Conditions: Suicidal Ideation | Phase 2 | Status: WITHDRAWN